Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Cash Flows

v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2025
Oct. 31, 2024
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (11,028) $ (12,698)
Stock option compensation to employees and directors 3,681 4,420
Stock options issued to consultants 129 125
Common stock issued to consultants 255
Amortization of operating lease right-of-use asset 36 37
Amortization of discount on held-to-maturity securities (143)
Change in operating assets and liabilities:    
Receivables 173 97
Prepaid expenses and other current assets 552 (23)
Accounts payable (360) 319
Accrued expenses (185) 176
Operating lease liability (28) (43)
Net cash used in operating activities (7,173) (7,335)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (44,360) (63,770)
Proceeds from maturities of short-term investments 49,226 68,046
Net cash provided by investing activities 4,866 4,276
Cash flows from financing activities:    
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $183 and $168, for the years ended October 31, 2025 and 2024, respectively 2,378 2,955
Proceeds from sale of common stock pursuant to employee stock purchase plan 7 10
Net (costs) proceeds from exercise of stock options (105) 456
Disbursements for purchases of treasury stock (6)
Net cash provided by financing activities 2,280 3,415
Net (decrease) increase in cash and cash equivalents (27) 356
Cash and cash equivalents at beginning of year 1,271 915
Cash and cash equivalents at end of year 1,244 1,271
Supplemental cash flow information:    
Cash proceeds from interest income 686 1,230
Supplemental disclosure of non-cash investing activity:    
Modification to operating lease right-of-use asset (100)
Supplemental disclosure of non-cash financing activity:    
Modification to operating lease liability $ 100